The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

How George Tidmarsh crossed the FDA-industry Rubicon

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

To say that it has been an eventful few months for George Tidmarsh would be a bit of an understatement.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
By Claire Marie Porter and Paul Goldberg
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account